Volume | 21,949 |
|
|||||
News | - | ||||||
Day High | 1.83 | Low High |
|||||
Day Low | 1.75 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
TRACON Pharmaceuticals Inc | TCON | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.77 | 1.75 | 1.83 | 1.79 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
95 | 21,949 | $ 1.78 | $ 38,994 | - | 1.59 - 17.59 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:00:54 | 95 | $ 1.766 | USD |
TRACON Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
81.45M | 45.50M | - | 12.05M | -3.59M | -0.08 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
TRACON Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TCON Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.12 | 2.14 | 1.70 | 1.88 | 126,405 | -0.36 | -16.98% |
1 Month | 8.834 | 8.834 | 1.59 | 4.41 | 2,394,280 | -7.07 | -80.08% |
3 Months | 3.98 | 14.746 | 1.59 | 7.25 | 3,518,853 | -2.22 | -55.78% |
6 Months | 3.40 | 14.746 | 1.59 | 5.30 | 4,185,414 | -1.64 | -48.24% |
1 Year | 17.20 | 17.59 | 1.59 | 5.34 | 2,349,278 | -15.44 | -89.77% |
3 Years | 152.20 | 161.60 | 1.59 | 11.64 | 886,134 | -150.44 | -98.84% |
5 Years | 13.80 | 244.00 | 1.59 | 33.46 | 751,191 | -12.04 | -87.25% |
TRACON Pharmaceuticals Description
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, TJ4309, Bispecific Antibodies. |